Abstract
Background
Off-label outpatient parenteral ketamine programs are expanding, yet rare perisession events requiring urgent escalation of care are difficult to quantify for local risk management. This documentation-based audit estimates denominator-based upper bounds for prespecified onsite escalation-of-care actions; it does not assess efficacy or long-term outcomes.
Methods
Retrospective chart audit of routine outpatient IV/IM ketamine sessions at two anesthesiology clinics in Japan (Nagoya: January 2010–June 2025; Tokyo: December 2024–June 2025). Adults (≥18 years) with ≥1 parenteral session were included. Two clinicians audited each session record for Tier 1 escalation-of-care events from initiation until discharge; session counts were reconciled with operational records. Exact one-sided 95% upper confidence bounds were calculated under zero events.
Results
Among 299 unique adults identified, 296 received ≥1 parenteral session (1985 sessions: IV 1779; IM 206). No Tier 1 events were chart-documented (0/1985), yielding a one-sided 95% upper confidence bound of 0.15% per session (IV 0.17%; IM 1.44%); the patient-level upper bound was 1.01% (0/296). A fall requiring ambulance transport was documented after formal discharge (outside the prespecified onsite perisession observation window).
Conclusions
Over a 15-year program horizon, no Tier 1 escalation-of-care events were chart-documented during the onsite perisession window. Findings provide documentation-based upper bounds for rare, high-acuity onsite events relevant to monitoring and rescue planning, but may underestimate reactions not prompting urgent intervention and harms after discharge.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
